US Patent

US8399514 — Treatment for multiple sclerosis

Method of Use · Assigned to Biogen Idec MA Inc · Expires 2028-02-07 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using certain compounds to treat neurological diseases, such as multiple sclerosis, by slowing or reducing demyelination and cell death.

USPTO Abstract

Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1384 — Tecfidera
U-1384 — Tecfidera

Patent Metadata

Patent number
US8399514
Jurisdiction
US
Classification
Method of Use
Expires
2028-02-07
Drug substance claim
No
Drug product claim
No
Assignee
Biogen Idec MA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.